

MEDICAL TECHNOLOGY M&A PULSE

FOURTH QUARTER 2022



Q4'22

INSIDE THIS ISSUE

Trends in Medical Technology	PAGE 4
Medical Technology M&A Activity	PAGES 5-9
2022 Q4 Public Market Summary	PAGES 10-13
Venture Capital Activity Overview	PAGE 14

PMCF Medical Technology Team

ABOUT PMCF

PMCF is an investment bank focused exclusively on middle market transactions with professionals in Chicago, Detroit, Denver, and across the globe through Corporate Finance International™ affiliates. Offering a depth of advisory services, PMCF helps clients worldwide meet their sale, acquisition, financing, and strategic growth objectives. Additional information on PMCF can be found by visiting our website, pmcf.com.

INVESTMENT BANKING SERVICES:

- Mergers & Acquisitions
- Carve-outs & Divestitures
- Strategic Assessments
- Transaction Readiness Planning
- Capital Raising



BRYAN HUGHES
Managing Director
312.602.3636
Bryan.Hughes@pmcf.com



MATT JAMISON
Managing Director
312.602.3583
Matt.Jamison@pmcf.com



MIKE BROOKS
Vice President
312.602-3644
Mike.Brooks@pmcf.com



JAKE STESLICKI
Vice President
312.602.3674
Jake.Steslicki@pmcf.com

Medical Technology Industry Expertise

In the medical technology sector, it takes a highly focused approach to execute a transaction efficiently. And it requires the constant monitoring of new procedures, technology and product development, and overall market trends. At PMCF, our Medical Technology team brings this dedication and market knowledge to every transaction. Our transaction expertise in the medical device, bio-pharmaceutical, and healthcare sectors, combined with industry relationships and a proprietary healthcare consulting service offering, afford us a unique perspective in the industry.

Medical Devices	Contract Research	Clinical Services	Therapeutics
Healthcare	Contract Manufacturing	Behavioral Health	Managed Care
Drug Delivery	Bio-Pharmaceutical	Specialty Pharmacy	Specialty Services

SELECT RECENT PMCF MEDICAL TECHNOLOGY TRANSACTIONS



2022 Q4 Market Summary


Q4 2022: A LATE BOUNCE IN A CHALLENGING YEAR

- 2022's fourth quarter was a welcome change from the rest of the year in terms of public market performance. After heavy declines throughout the first three quarters, Q4 marked a return to stability in the benchmark S&P 500 Growth Index, which was down just 0.8%. Underlying macro factors such as unemployment continue to paint an optimistic picture, while consumer price data indicates a slowing of the inflation that has characterized much of the past two years.
- M&A activity slowed from 2021's torrid pace, though transactions were completed at a healthy clip relatively speaking, with fourth quarter volume up 0.6% compared to the average of the previous five years. Within Healthcare, Service companies were the most frequently acquired, making up 28.2% of 2022's transactions, followed by Medical Equipment which comprised 22.0%.
- PMCF's four tracked medical subsector indices all outperformed the benchmark S&P 500 Growth Index during 2022, which was heavily impacted by large tech sector sell-offs. The Dow Jones Industrial Average was the big winner on the year, down a relatively mild 9.4%.

2022 NOTABLE EVENTS TIMELINE

- January 28, 2022 | Worldwide COVID-19 Vaccinations Exceed 10 Billion
- February 4, 2022 | 2022 Winter Olympics Begin in Beijing, China
- February 24, 2022 | Russia Invades Ukraine, Significantly Escalating Clashes in the Region
- May 5, 2022 | Dow Drops More Than 1,100 Points Over Interest Rate Concerns
- May 19, 2022 | First Monkeypox Case of the Year Reported in the US
- June 13, 2022 | Average US Gas Price Hits \$5 for the First Time Ever
- June 24, 2022 | Supreme Court Overturns Roe v. Wade
- July 8, 2022 | Shinzo Abe, Former Prime Minister of Japan is assassinated
- September 8, 2022 | Queen Elizabeth II dies
- October 28, 2022 | Elon Musk completes \$44B acquisition of Twitter
- November 11, 2022 | Cryptocurrency exchange FTX files for Chapter 11 bankruptcy


PMCF MEDICAL TECHNOLOGY INDICES PERFORMANCE



Sources: Capital IQ, PitchBook, Company Reports, Fraser


Trends in Medical Technology

U.S. PERSONAL HEALTH CARE SERVICES EXPENDITURES (\$B)




- Real disposable personal income refers to the amount U.S. residents have left to spend after paying taxes, adjusted for inflation. It has historically been relatively stable and increasing, though it recently went through a period of volatility during the pandemic.
- For various segments of the healthcare industry, spending on healthcare is correlated with disposable income, making it a valuable macroeconomic indicator. Year end total disposable income was \$15.1B, nearly flat for the entirety of 2022.

U.S. PERSONAL HEALTH CARE SERVICES EXPENDITURES (\$B)



- Personal Health Care Service expenditures serve as a proxy for activity in the broader Healthcare and Medical industries, with high levels of service expenditures correlated with strong performance in other sectors.
- Health care service expenditures recovered from the disruptions and temporary delays of elective procedures during the pandemic. Total expenditures now exceed pre-pandemic levels and are growing notably, up 4.9% over the last year.

MEDICAL EQUIPMENT & SUPPLY PRODUCER PRICE INDEX (PPI)



- As in the broader U.S. economy, medical equipment producer costs have dramatically risen coming out the pandemic. The Bureau of Labor Statistics provides a Producer Price Index (PPI) that measures the average change in selling price of domestic output. The Medical Equipment & Supply PPI value serves as a broad proxy for Medical industry costs.
- The PPI is based on a 2003 baseline equal to 100. Currently the index is at 128.7, up from 125.4 at the beginning of 2022.

Sources: PMCF Research, FRED, US Census Bureau, IBIS

Medical Technology M&A Activity

Medical Equipment

Johnson & Johnson (NYSE:J) acquires Abiomed (Nasdaq:ABMD)

November 2022 — Johnson & Johnson (NYSE:JNJ) announced that it agreed to acquire all shares of Abiomed (Nasdaq:ABMD). Abiomed provides cardiovascular medical technology, particularly for the treatment of coronary artery disease and heart failure. The transaction is valued at ~\$16.6B. The acquisition seeks to expand J&J's platform of heart failure and recovery products, expanding market opportunities through new technologies. Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson said, "Abiomed's skilled workforce and strong relationships with clinicians, along with its innovative cardiovascular portfolio and robust pipeline, complement our MedTech portfolio, global footprint and robust clinical expertise. Together, we have the incredible opportunity to bring lifesaving innovations to more patients around the world." The transaction is expected to close in the first quarter of 2023 and is conditioned on the tender of a majority of the outstanding shares of Abiomed's common stock.

Therapeutic Device

Aspen Surgical acquires Symmetry Surgical

October 2022 — Aspen Surgical, a portfolio company of Audax Private Equity, announced the acquisition of Symmetry Surgical from RoundTable Healthcare Partners, a private equity firm focused on the healthcare industry. Symmetry is a manufacturer and distributor of reusable surgical instrumentation, electrosurgical products, and minimally invasive surgical devices. The Company's brands include Bookwalter, Bovie, Greenberg, Reddick, and The O.R. Company. Aspen pursued a transaction with Symmetry in order to augment their portfolio with additional clinically preferred brands and diversify into attractive adjacent categories. Brian Straeb, Chief Executive Officer of Symmetry said, "RoundTable has been an invaluable partner for Symmetry. They have supported us through strategic investments to enhance the commercial organization and multiple transformative acquisitions to build our portfolio of brands. We now look forward to entering our next phase of growth with Aspen." Transaction consideration details were not disclosed.

Consumable & Disposable

Berkeley Lights (Nasdaq:BLI) acquires IsoPlexis (Nasdaq:ISO)


December 2022 — Berkeley Lights (Nasdaq:BLI) announced a definitive agreement to acquire IsoPlexis (Nasdaq:ISO) in an all stock transaction valued at \$57.8M. IsoPlexis' labs provide insight into how multi-functional immune cells communicate and respond, assisting researchers in understanding and predicting disease progression, treatment, and resistance. Berkeley Lights is a life sciences tools company focused on the development of biotherapeutics, providing proprietary consumables, including OptoSelect chips and reagent kits, advanced automation systems, and software applications. IsoPlexis most recent earnings were approximately \$18.9M in revenue, valuing the transaction at just north of 3x EV / Revenue. Siddhartha Kadia, Ph.D., Chief Executive Officer of Berkeley Lights commented, "The combination of Berkeley Lights and IsoPlexis represents an important milestone and fuels our transformation into a growing, profitable, and sustainable life sciences company. This transaction accelerates our progress across every core pillar of our strategic plan and creates a path to achieving positive operating cash flow earlier than we expected to as a standalone company." The combined company will be named Phenomex (Nasdaq:CELL). The deal is expected to close during the first quarter of 2023, subject to approval by shareholders of both companies.

M&A Activity Roundup


TRENDS IN MEDICAL TECHNOLOGY M&A

- 2022 M&A volume was down 22.8%, following a record setting 2021. Fourth quarter M&A activity was up 21.2% compared to the previous quarter, finishing as the second strongest quarter in 2022, behind the second quarter. There have been 591 announced deals in 2022, more than in 2020, and almost identical to 2019's count.
- Throughout 2022, Services, Equipment, and Therapeutic Device transactions experienced the greatest volumes within medical M&A, similar to 2021. Consumable and Disposable experienced a notable quarter over quarter volume increase, climbing from 14 transactions in Q3 to 30 in Q4.
- Of the 2022 transactions with disclosed EV and EBITDA, median TEV / EBITDA multiples rose slightly from the year prior (15.7 vs. 14.5x). Average transaction values for 2022 were lower than 2021, however were more in line with 2020 values.

TRANSACTIONS BY PRODUCT SEGMENT - Q4 2022



MEDICAL DEVICE M&A TRANSACTION METRICS



Period	Mean/Median	Transaction Value (\$MM)	TEV/REV	TEV/EBITDA
2022 Q4	Mean	\$698.9	4.00x	22.33x
2022 Q4	Median	\$37.6	2.42x	16.05x
2021 Q4	Mean	\$793.9	3.38x	18.00x
2021 Q4	Median	\$72.0	2.53x	17.79x
2022	Mean	\$465.4	9.98x	27.01x
2022	Median	\$30.0	2.39x	15.70x
2021	Mean	\$634.0	6.11x	17.60x
2021	Median	\$60.7	3.71x	14.54x
2020	Mean	\$416.7	5.28x	30.54x
2020	Median	\$24.3	2.40x	13.57x


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Medical Equipment M&A


TRENDS IN MEDICAL EQUIPMENT M&A

- Medical Equipment M&A volume in 2022 saw a year-over-year decrease from 171 to 130 announced transactions. 2022 activity reverted back towards historical averages, with 2021 standing out as an outlier. Strategic acquirers continue to be the most active in the space, with 99 transactions announced during 2022, 31 of those in the fourth quarter.
- Private acquirers were the most active in Q4 and all of 2022, comprising 46% and 44% of total announced transactions respectively. Public acquirers were the second most active group throughout the year, albeit at a lower pace than in 2021 (42 in 2022 vs. 80 in 2021).
- International acquisitions in 2022 kept pace with 2021 levels, while domestic M&A experienced a modest pullback year-over-year. Cross border transactions were light in the fourth quarter, but remained in line with historical averages.
- Furniture/Equipment was the leading end market within the broader Medical Equipment category. Surgical, Monitor, and Hospital Care followed behind as the next most active markets in the subsector.

FINANCIAL VS. STRATEGIC BUYER MEDICAL EQUIPMENT



MEDICAL EQUIPMENT TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2020	2021	2022	21 Q4	22 Q4
Acute Care	4	2	-	2	-
Aesthetic	-	1	3	1	-
Cardiovascular	3	4	5	-	2
Drug Delivery	5	8	1	2	-
Furniture/Equipment	25	37	28	6	6
Home Health	9	11	8	4	1
Hospital Care	21	19	13	2	1
Infection Control	1	2	3	1	1
IVD	1	6	3	2	-
Monitor	12	16	15	3	4
Neurovascular	2	2	-	-	-
Ophthalmology	6	8	5	2	2
Ortho	-	6	8	1	4
Other	11	10	5	1	3
Respiratory	6	12	6	1	2
Support	6	11	10	3	5
Surgical	17	16	17	3	8
Total	129	171	130	34	39

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2020	2021	2022	21 Q4	22 Q4
Int'l-to-Int'l	57	62	62	12	22
U.S.-to-Int'l	12	16	12	3	1
U.S.-to-U.S.	46	76	43	15	14
Int'l-to-U.S.	14	17	13	4	2
Total	129	171	130	34	39


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Therapeutic Device M&A

TRENDS IN THERAPEUTIC DEVICE M&A

- Therapeutic Device M&A volume was meaningfully down in 2022 compared to 2021, with 37 fewer announced transactions. 2022 had 104 announced transactions, right between 2019 and 2020 activity levels (102 and 117 transactions), respectively.
- Private acquirers in 2022 nearly kept pace with volume from the year prior, with 24 announced transactions, compared to 30 in 2021. Public acquirers remained the most active group, participating in 53% of Therapeutic Device transactions announced in 2022.
- Ophthalmology, Ortho, and diversified Other were the top three end markets in 2022. These markets collectively made up 59% of transactions. Neurovascular had a strong 2022, with 3 of 10 total transactions in the fourth quarter.
- While 2022 experienced lower volumes compared to the record 2021 year, the trend of purely domestic and purely international leading transaction volumes persisted. Conversely, U.S. acquirers remained interested in international targets, with 13 transactions, exceeding 2021 and experiencing similar activity as 2020.


FINANCIAL VS. STRATEGIC BUYER THERAPEUTIC DEVICE



TRANSACTIONS BY END MARKET

End Market	2020	2021	2022	21 Q4	22 Q4
Acute Care	3	3	3	-	-
Aesthetic	-	1	3	-	2
Cardiovascular	10	18	9	5	-
Drug Delivery	2	-	3	-	-
Furniture/Equipment	3	2	1	-	1
Home Health	5	7	1	3	1
Hospital Care	-	1	1	-	1
Infection Control	-	2	-	1	-
IVD	1	1	-	-	-
Monitor	2	-	1	-	1
Neurovascular	1	4	10	-	3
Ophthalmology	7	15	20	4	2
Ortho	37	28	18	5	5
Other	36	45	23	10	4
Respiratory	3	8	3	2	1
Support	2	5	2	-	-
Surgical	5	1	6	-	2
Total	117	141	104	30	23

THERAPEUTIC DEVICE TRANSACTIONS BY BUYER TYPE



CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2020	2021	2022	21 Q4	22 Q4
Int'l-to-Int'l	47	61	45	13	10
U.S.-to-Int'l	10	10	8	2	5
U.S.-to-U.S.	46	59	38	11	7
Int'l-to-U.S.	14	11	13	4	1
Total	117	141	104	30	23


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Consumable & Disposable M&A


TRENDS IN CONSUMABLE & DISPOSABLE M&A

- Consumable & Disposable M&A modestly fell in 2022, moving from 79 to 67 announced transactions. The fourth quarter of 2022 produced 30 transactions, notably higher than the final quarter of 2021.
- Transactions in 2022 were nearly evenly spread among private acquirers, public acquirers, and private equity groups, a material change from 2021, which saw 50% of transactions come from public acquirers. Private equity acquirers remained equally interested in Consumable & Disposable markets, announcing 22 transactions in 2022 compared to 26 in 2021 and 13 in 2020.
- Similar to the Therapeutic Device segment trends, purely international activity was strong on a year-over-year basis, comprising nearly 60% of all announced transactions. Domestic volumes remained strong, particularly when compared to 2021.
- Through 2022, Infection Control remained the most active end market in the sector. Surgical was just behind as the next most common end market, seeing 3 of the 11 transactions in 2022 come in the final quarter.

FINANCIAL VS. STRATEGIC BUYER CONSUMABLE & DISP.



CONSUMABLE & DISP. TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2020	2021	2022	21 Q4	22 Q4
Acute Care	8	9	1	3	-
Aesthetic	-	1	3	1	1
Cardiovascular	-	-	1	-	1
Drug Delivery	8	4	3	-	-
Furniture/Equipment	-	1	-	-	-
Home Health	2	2	1	-	-
Hospital Care	6	14	-	2	-
Infection Control	18	27	21	7	6
IVD	1	3	3	-	2
Monitor	-	1	-	1	-
Neurovascular	-	-	1	-	1
Ophthalmology	1	1	3	-	3
Ortho	1	-	3	-	1
Other	11	4	7	1	5
Respiratory	2	-	1	-	1
Support	3	6	9	2	5
Surgical	-	6	11	1	3
Total	61	79	68	18	29

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2020	2021	2022	21 Q4	22 Q4
Int'l-to-Int'l	35	41	39	10	14
U.S.-to-Int'l	4	8	5	2	3
U.S.-to-U.S.	21	23	20	3	9
Int'l-to-U.S.	1	7	4	3	3
Total	61	79	68	18	29

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Medical Device Public Comparables

PUBLIC DIVERSIFIED MEDICAL DEVICE COMPANY COMMENTARY


- We saw the U.S. dollar strengthened significantly and inflation reached new heights last year. Supply chains continue to face challenges, and our health care customers have been navigating staffing challenges that are negatively impacting certain medical device procedure trends and routine diagnostic testing volumes. As we start the new year, however, while all these factors remain headwinds, I'm cautiously optimistic that we're starting to see them peak and, in some cases, ease a bit." – Robert Ford, Abbott Laboratories, Chairman of the Board, President & CEO
- "Procedural volumes continue to recover throughout the fourth quarter in most countries. Parts of Asia Pacific, however, have continued to be more volatile due to ongoing COVID-related impacts." – Jason Beach, Stryker VP Investor Relations

DIVERSIFIED MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	12/31/2022	9,907	16,580	191,427	198,309	4.4x	14.1x	24.8x
Baxter International Inc.	9/30/2022	1,601	16,886	25,695	41,024	2.8x	13.1x	NM
Becton, Dickinson and Company	12/31/2022	612	16,456	72,289	88,135	4.7x	17.6x	47.3x
Boston Scientific Corporation	12/31/2022	338	8,934	66,273	74,869	6.0x	22.1x	110.7x
Intuitive Surgical, Inc.	12/31/2022	6,742	0	93,771	87,029	14.6x	44.5x	70.3x
Johnson & Johnson	10/2/2022	34,079	32,027	461,849	459,797	4.8x	14.2x	24.6x
Medtronic plc	10/28/2022	11,430	26,617	103,382	118,746	3.9x	12.9x	24.1x
Smith & Nephew plc	7/2/2022	516	2,893	11,624	14,001	2.7x	11.2x	23.6x
Stryker Corporation	12/31/2022	1,928	11,857	92,522	102,451	5.8x	22.7x	38.0x
High		34,079	32,027	461,849	459,797	14.6x	44.5x	110.7x
Mean		7,461	14,694	124,315	131,596	5.5x	19.2x	45.4x
Median		1,928	16,456	92,522	88,135	4.7x	14.2x	31.4x
Low		338	0	11,624	14,001	2.7x	11.2x	23.6x

As of December 31, 2022

DIVERSIFIED MEDICAL DEVICE MULTIPLES



DIVERSIFIED MEDICAL DEVICE INDEX



EV/EBITDA multiples for the Diversified Medical Device ("DMD") sector finished 2022 down 13.0% from a year ago, 19.2x vs 22.0x, with revenue multiples down similarly, 5.5x vs. 6.9x. No company in the sector had a higher EBITDA multiple at year end than Intuitive Surgical, which traded at 44.5x. Stryker and Boston Scientific were the next highest, each between 22.0x – 23.0x. Becton, Dickinson and Company had the largest multiple growth during the year, increasing 15.9% from 15.1x to 17.6x, while Abbott had the largest decline, down 28.4%.

The DMD index was the best performing of the PMCF tracked indices, finishing the year down 10.7% on the year. This far exceeded the performance of the benchmark S&P 500 Growth Index which was down 30.6% during the same period.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Orthopedic Public Comparables

PUBLIC ORTHOPEDIC MEDICAL DEVICE COMPANY COMMENTARY


- “[I]f you’re going to dominate lateral surgery, a foundational requirement is neuromonitoring. And there’s no way around it. And having been at this for north of 20 years, you’re not getting around being a player in lateral surgery without neuromonitoring. It’s really why we focus so much effort and garnered so much expertise in this area.” – Patrick S. Miles, Alphatec Executive Chairman, CEO & President
- “Back pain is a big problem. It’s obviously problematic if you are suffering from back pain, but the societal challenge that we face. We’ve got a growing population, an aging population, high prevalence, significant cost to treat. And as you see down below, the #1 reason for disability is back pain.” – J. Christopher Barry, NuVasive CEO & Director

ORTHOPEDIC MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Alphatec Holdings, Inc.	9/30/2022	106	393	1,297	1,608	5.0x	NM	NM
Enovis Corporation	9/30/2022	255	525	2,898	3,169	0.8x	5.2x	14.9x
Globus Medical, Inc.	9/30/2022	405	0	7,415	7,010	6.5x	24.2x	49.6x
NuVasive, Inc.	9/30/2022	238	1,007	2,150	2,920	2.4x	12.4x	NM
Orthofix Medical Inc.	9/30/2022	52	27	411	386	0.8x	22.3x	NM
Smith & Nephew plc	7/2/2022	516	2,893	11,624	14,001	2.7x	11.2x	23.6x
Stryker Corporation	12/31/2022	1,928	11,857	92,522	102,451	5.8x	22.7x	38.0x
Surgalign Holdings, Inc.	9/30/2022	14	11	25	23	0.3x	NM	NM
Zimmer Biomet Holdings, Inc.	12/31/2022	376	5,697	26,756	32,077	4.1x	12.9x	82.9x
High		1,928	11,857	92,522	102,451	6.5x	24.2x	82.9x
Mean		432	2,490	16,122	18,183	3.2x	15.8x	41.8x
Median		255	525	2,898	3,169	2.7x	12.9x	38.0x
Low		14	0	25	23	0.3x	5.2x	14.9x

As of December 31, 2022

ORTHOPEDIC MEDICAL DEVICE MULTIPLES



ORTHOPEDIC MEDICAL DEVICE INDEX



Collectively Orthopedic Medical Device multiples declined 4.4% compared to 2021. The sector had significant variance, with Orthofix experiencing a 60.3% increase in multiple during the year while NuVasive had a 22.3% decline. Both Alphatec and Surgalign did not report EBITDA multiples for the year, as they were not profitable on an EBITDA basis. Cash reserves for each company are low, making them situations worth monitoring during 2023.

The OMD index was the second-best performer of PMCF’s tracked, indices, down 11.3%, just behind the DMD index. The OMD had a strong fourth quarter, increasing 14.8% over the 3-month period.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Cardiovascular Public Comparables

PUBLIC CARDIOVASCULAR MEDICAL DEVICE COMPANY COMMENTARY


- “Despite the impact we believe COVID and medication changes had on the ambulatory endpoint in ON MED, the totality of the data is compelling. The large drop in office blood pressure in the Ardian arm was impressive, and it was consistent with what we’ve seen in our other trials. Importantly, the current standard of care for reducing blood pressure, it just isn’t working” – Geoff Martha, Medtronic CEO & Chairman of the Board
- “Growth in the U.S. was higher in larger volume centers and in states with fewer Covid restrictions as measured by the Daxferns Containment and Health Index. We’re encouraged by recent hiring trends, which suggests that hospital employment is rebounding.” – Michael Mussallem, Edwards Lifesciences Chairman & CEO

CARDIOVASCULAR MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	12/31/2022	9,907	16,580	191,427	198,309	4.4x	14.1x	24.8x
AngioDynamics, Inc.	11/30/2022	30	56	539	564	1.8x	67.6x	NM
Cardiovascular Systems, Inc.	9/30/2022	144	22	570	449	1.9x	NM	NM
Artivion, Inc.	9/30/2022	38	356	489	807	2.6x	35.3x	0.0x
Edwards Lifesciences Corporation	12/31/2022	1,215	691	46,128	45,604	8.4x	23.8x	32.2x
LeMaitre Vascular, Inc.	9/30/2022	80	17	1,012	949	5.9x	21.4x	48.4x
Medtronic plc	10/28/2022	11,430	26,617	103,382	118,746	3.9x	12.9x	24.1x
Merit Medical Systems, Inc.	9/30/2022	51	287	4,020	4,255	3.7x	19.5x	66.7x
Terumo Corporation	9/30/2022	1,471	1,656	21,151	21,336	3.7x	16.4x	35.8x
High		11,430	26,617	191,427	198,309	8.4x	67.6x	66.7x
Mean		2,707	5,142	40,969	43,447	4.0x	26.4x	33.1x
Median		144	356	4,020	4,255	3.7x	20.4x	32.2x
Low		30	17	489	449	1.8x	12.9x	0.0x

As of December 31, 2022

CARDIOVASCULAR MEDICAL DEVICE MULTIPLES



CARDIOVASCULAR MEDICAL DEVICE INDEX



Cardiovascular Medical Devices EBITDA and revenue multiples finished 2022 at 26.4x and 4.0x, their lowest valuation levels since 2016. AngioDynamics retained its premium valuation throughout the year, closing at 67.6x EBITDA. Edwards Lifesciences had the highest revenue multiple, finishing at 8.4x, though that was a nearly 50% decline from the 15.7x it closed 2021 at.

The CMD index had an almost flat fourth quarter, declining just 0.8%. For the year the index was down 29.6%, just barely outperforming the benchmark S&P 500 Growth Index but trailing all other PMCF tracked medical indices.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Diagnostic Public Comparables

PUBLIC DIVERSIFIED DIAGNOSTIC COMPANY COMMENTARY


- “Quite frankly, the best thing we can do for the world, and also for our business, is to raise awareness and opportunities for women’s health globally. For a sense of scale, there are approximately 170 million women in the U.S., our largest market.” – Steve MacMillan, Hologic, Chairman, President, & CEO
- “China grew low single digits, driven by robust demand in our life sciences instruments and acute care diagnostic businesses. However, the reopening efforts associated with the ending of zero COVID policies and subsequent increase in COVID-19 infections resulted in reduced patients and testing volumes in our clinical diagnostics business. We anticipate lower testing volumes to continue through the first quarter of 2023.” – Rainer Blair, Danaher President & CEO

DIVERSIFIED DIAGNOSTIC PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	12/31/2022	9,907	16,580	191,427	198,309	4.4x	14.1x	24.8x
Becton, Dickinson and Co.	12/31/2022	612	16,456	72,289	88,135	4.7x	17.6x	47.3x
Danaher Corporation	12/31/2022	5,995	19,677	193,216	208,574	6.7x	18.7x	29.3x
Hologic, Inc.	12/31/2022	2,476	2,848	18,391	18,762	3.9x	9.0x	14.6x
Laboratory Corporation of America	9/30/2022	410	6,354	20,864	26,826	1.8x	7.8x	12.5x
Novartis AG	12/31/2022	18,726	27,964	194,448	203,767	3.7x	5.6x	8.7x
Quest Diagnostics Incorporated	12/31/2022	315	4,622	17,817	22,238	2.1x	8.1x	15.3x
Roche Holding AG	6/30/2022	7,130	30,439	280,280	307,524	4.2x	11.0x	16.5x
Thermo Fisher Scientific Inc.	12/31/2022	8,524	34,488	216,998	243,078	5.5x	19.4x	31.0x
High		18,726	34,488	280,280	307,524	6.7x	19.4x	47.3x
Mean		6,011	17,714	133,970	146,357	4.1x	12.4x	22.2x
Median		5,995	16,580	191,427	198,309	4.2x	11.0x	16.5x
Low		315	2,848	17,817	18,762	1.8x	5.6x	8.7x

As of December 31, 2022

DIVERSIFIED DIAGNOSTIC MULTIPLES



DIVERSIFIED DIAGNOSTIC INDEX



EV/EBITDA multiples within the Diversified Diagnostic (“DD”) industry closed down 11.9% from 2021’s year end to 2022’s. Company level performance was mixed, with 4 of the 9 index members up during the year. These performance leaders were Becton, Dickinson and Company, up 15.9%, Hologic, up 23.7%, Johnson & Johnson up 10.8%, and Novartis up 14.2%. Aside from these big gainers, most of the remainder of the index struggled, with Thermo Fisher down 3.7% and the remaining companies down at least 18.0%.

The DD Index was down 14.6% over the 2022 trading year. Despite the negative outcome, the fourth quarter was a bright spot, with the index increasing 4.6% during the quarter, indicating some positive momentum heading into 2023.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

2022 Venture Capital Activity Overview


If 2022 were compared to any year other than 2021 it would appear to be an all-time positive outlier, perhaps the greatest in industry history. Both volume and deal valuations were at near historic highs, and VC funds raised enormous amounts of capital to invest. That said, it was a significant step down from last year, and intra-year trends were not encouraging. Both activity and valuations declined meaningfully between Q1 and Q4, while down rounds became commonplace in the second half of the year as companies sought to ensure runway and conserve cash. Most investors expect 2023 to continue trends from 2022's 2H, with some optimism around growth returning later in the year.

Rising interest rates have driven many large institutional LPs to shift allocations away from the venture asset class, able to generate returns via less volatile, more liquid investment types. Industry experts are predicting a continued decline in fundraising activity in 2023, coupled with increasing capital concentration among the largest funds in the industry. This is thought to be driven by the lower perceived risk of investing with established firms, as well as the ease of avoiding the time and cost intensive process of performing diligence on a new fund.


Total deal value for 2022 decreased 69.9% from 2021 (and increased 58.9% from 2019, the last pre-COVID year). Transaction count declined 14.4% from 2021, indicating that much of the pullback in value year over year was driven by deals at the very top end of the size spectrum. Analyzing deal valuations by stage, 3 of the 4 cohorts saw growth in 2022, with angel up 9.7%, seed up 16.7%, and early VC up 19.0%. Only late VC was down for the year, coming in 10.2% lower by median valuation.

All three of the healthcare industry subsectors had a decline in deal volume relative in 2022. Pharma & Biotech was down 25.5%, while HC Devices & Supplies was down 17.6% and HC Services & Systems was down 16.0%. With that said, compared to 2019, deal count was up for HC Services & Systems and Pharma & Biotech, and down just 3.4% for HC Devices & Systems.


VC INVESTMENTS IN MEDICAL SECTORS



MEDIAN PRE-MONEY VALUATION BY ROUND



DEAL COUNT BY ROUND



Angel/Seed: The company has a concept or product under development, but is likely not fully operational. Typically in existence less than 18 months.

Early: The company has a product or service in testing or pilot production. In some cases, the product may be commercially available. May or may not be generating revenues. Typically in business less than three years.

Later: Product or service is widely available. Company is generating ongoing revenue; potentially positive cash flow. More likely to be, but not necessarily, profitable.

Sources: Capital IQ, PitchBook, NVCA, PMCF

PMCF's Unique Approach to M&A Advisory

PMCF's M&A advisory and investment banking services are designed to provide company shareholders with a trusted advisor to oversee all transaction related aspects of a company sale or strategic acquisition. Our service levels, industry expertise in medical technology, and approach to managing transactions positions us favorably against a traditional investment banker. See below for some examples of our differentiation:

- Differentiated approach via senior banker leadership and direct involvement through every step of the transaction providing a consistent and highly experienced point of contact
- One of the largest, most active investment banking boutiques with a focus on specialty niche businesses
- Proven positioning and marketing processes to obtain premium valuations in company sales
- Tailored sale process provides for extensive upfront preparation, detailed company review and identification of any potential issues in advance, and buyer evaluation/diligence ensuring the right fit
- Unique sale planning approach that helps shareholders best prepare for a future sale whether its six months or several years
- Long-term and client first approach allows PMCF to provide unbiased advice



Two-time winner, Boutique Investment Banking Firm of the Year
by M&A Advisor

Awarded, Cross Border Corporate and Strategic Acquisition of the Year
by M&A Advisor

Awarded, Cross Border M&A Deal of the Year
by M&A Advisor

Awarded, Deal of the Year
by ACG Detroit

Contact Info

PMCF | INVESTMENT
BANKING



CHICAGO

120 S. Riverside Plaza
Suite 2100
Chicago, IL 60606
Phone: 312.602.3600



DETROIT

2 Towne Square
Suite 425
Southfield, MI 48076
Phone: 248.223.3300



DENVER

8181 E. Tufts Avenue
Suite 600
Denver, CO 80237
Phone: 720.370.8181

120 S Riverside Plaza
Suite 2100
Chicago, IL 60606

Experienced Professionals. Trusted Advisors. Proven Results.

This market overview is not an offer to sell or a solicitation of an offer to buy any security. It is not intended to be directed to investors as a basis for making an investment decision. This market overview does not rate or recommend securities of individual companies, nor does it contain sufficient information upon which to make an investment decision.

PMCF will seek to provide investment banking and / or other services to one or more of the companies mentioned in this market overview. PMCF and / or the analysts who prepared this market update, may own securities of one or more of the companies mentioned in this market overview.

The information provided in this market overview was obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. It is not to be construed as legal, accounting, financial, or investment advice. Information, opinions, and estimates reflect PMCF's judgment as of the date of publication and are subject to change without notice. PMCF undertakes no obligation to notify any recipient of this market overview of any such change.

The charts and graphs used in this market overview have been compiled by PMCF solely for illustrative purposes. All charts are as of the date of issuance of this market overview, unless otherwise noted.

The Medical Technology Index may not be inclusive of all companies in the medical technology industry and is not a composite index of the medical technology industry sector returns. Index and sector returns are past performance, which is not an indicator of future results.

This market overview is not directed to, or intended for distribution to, any person in any jurisdiction where such distribution would be contrary to law or regulation, or which would subject PMCF to licensing or registration requirements in such jurisdiction.

PMCF is a trade name for PMCF Advisors, LLC and P&M Corporate Finance, LLC, a FINRA-registered broker-dealer and SIPC member firm. The term "PMCF" refers to one or more of these legally separate and independent advisory practices. P&M Corporate Finance, LLC provides capital-raising and private placement services that require registration as a broker-dealer. PMCF Advisors, LLC provides M&A-related services that do not require registration in reliance upon the SEC M&A Brokers No-action Letter (2014) and comparable state-level exemptive relief. Please see pmcf.com to learn more.

For more information, check out our new website, where you can access the electronic version of this report, sign up for future emails, read our latest industry reports, and more!

